EUVIMEDEUVIMED entdecken
Crossref

Aerosol technology to mimic dry powder inhalation in vitro using pulmonary cell models

Adriana M Ledo, Stefan Thibodeaux, Lisa Duong, Erhan Altinoglu, Thomas Dimke, Duncan Shaw, David Rowlands, Ellena Growcott

European Journal of Pharmaceutics and Biopharmaceutics · 2023

DOI: 10.1016/j.ejpb.2023.05.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Adriana M Ledo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Disease Area X, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States. Hauptthemen laut MEDLINE: Lung, Technology. Die Arbeit nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhaled therapy confers key advantages for the treatment of topical pulmonary diseases and offers potential for systemic delivery of medicines. Dry powder inhalers (DPIs) are generally the preferred devices for pulmonary delivery due to improved stability and satisfactory patient compliance. However, the mechanisms governing drug powder dissolution and availability in the lung and poorly understood. Here, we report a new in vitro system to study epithelial absorption of inhaled dry powders in lung barrier models of the upper and lower airway. The system is based on a CULTEX® RFS (Radial Flow System) cell exposure module joined to a Vilnius aerosol generator and allows the coupling of drug dissolution and permeability assessments. The cellular models recapitulate the barrier morphology and function of healthy and diseased pulmonary epithelium and incorporate the mucosal barrier to enable the investigation of drug powder dissolution in biorelevant conditions. With this system, we found differences in permeability across the airway tree and pinpointed the impact of diseased barriers in paracellular drug transport. Furthermore, we identified a different rank order of permeability for compounds tested in solution or powder form. These results highlight the value of this in vitro drug aerosolization setup for use in research and development of inhaled medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LungTechnologyHumansPowdersAerosolsAdministration, InhalationDry Powder InhalersParticle Size

Stichwörter der Autor:innen

CULTEX® RFSDry powder aerosolsIn vitro lung barrier modelsInhalationLung permeabilityTranswell®

Substanzen

PowdersAerosols

Autor:innen und Institutionen

  • Disease Area X, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland.
  • Disease Area X, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States. Electronic address: ellie.growcott@novartis.com.

Zitieren

APA

Ledo, A. M., Thibodeaux, S., Duong, L., Altinoglu, E., Dimke, T., Shaw, D., Rowlands, D., & Growcott, E. (2023). Aerosol technology to mimic dry powder inhalation in vitro using pulmonary cell models. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.05.009

Vancouver

Ledo AM, Thibodeaux S, Duong L, Altinoglu E, Dimke T, Shaw D, et al. Aerosol technology to mimic dry powder inhalation in vitro using pulmonary cell models. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.05.009

BibTeX
@article{Ledo2023,
  author = {Ledo, Adriana M and Thibodeaux, Stefan and Duong, Lisa and Altinoglu, Erhan and Dimke, Thomas and Shaw, Duncan and Rowlands, David and Growcott, Ellena},
  title = {Aerosol technology to mimic dry powder inhalation in vitro using pulmonary cell models},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  doi = {10.1016/j.ejpb.2023.05.009}
}
Kostenlos starten →